Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial

Adipose-derived mesenchymal stem cell therapy in the treatment of knee osteoarthritis: a randomized controlled trial

International Archives of Medicine

 

Source

Regen.Med.(2019)14(3),213–230    10.2217/rme-2018-016 C 2019 Julien Freitag

Julien Freitag*, Dan Bates, James Wickham, Kiran Shah, Leesa Huguenin, Abi Tenen, Kade Paterson & Richard Boyd

School of Biomedical Sciences, Charles Sturt University, NSW, Australia/Melbourne Stem Cell Centre, VIC, Australia/Magellan Stem Cells, VIC, Australia/Faculty of Science, Engineering & Technology, Swinburne University of Technology, VIC, Australia/Monash University, VIC, Australia/Melbourne School of Health Sciences, The University of Melbourne, VIC, Australia/The Hudson Institute, VIC, Australia *Author for correspondence: Fax: +613 9890 3276; [email protected]

 

Abstract

To evaluate the efficacy of autologous adipose-derived mesenchymal stem cell (ADMSC) therapy on pain, function and disease modification in knee osteoarthritis. Methods: 30 participants with symptomatic knee osteoarthritis were randomized into three groups. Two treatment groups received intra-articular ADMSC therapy consisting of either a single injection (100 × 106 ADMSCs) or two injections (100 × 106ADMSCs at baseline and 6 months). The third group served as control and continued conservative management.

 

Conclusion

OA is a cause of significant morbidity and with an aging population it promises to remain an enormous community and economic burden. Current conservative management strategies fail to alter disease progression and surgical management in the form of joint replacement is associated with considerable risk. In this RCT, autologous ADMSC therapy was associated with clinically significant improvement in pain and function in symptomatic knee OA. These improvements were well beyond that achieved by conventional methods. Furthermore, ADMSCs were associated with successful disease modification with comparison of treatment protocols indicating that two intra-articular injections of ADMSCs separated by 6 months achieved more consistent OA stabilization than a single injection. Intra- articular autologous ADMSC therapy was shown to be safe with no serious AEs.

 

Study PDF Link 

Ready to make change?